Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Mertens AC, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 19(13), 3163–3172 (2001).
  Medline CASGoogle Scholar
• 2 Van Dalen EC, Van Der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur. J. Cancer 42(18), 3191–3198 (2006).
  Medline CASGoogle Scholar
• 3 Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4), 525–533 (2008).
  Medline CASGoogle Scholar
• 4 Kremer LC, Van Der Pal HJ, Offringa M, Van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. 13(6), 819–829 (2002).
  Medline CASGoogle Scholar
• 5 Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(12), 2629–2636 (2005).
  Medline CASGoogle Scholar
• 6 Van Der Pal HJ, Van Dalen EC, Hauptmann M et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch. Intern. Med. 170(14), 1247–1255 (2010).
  Medline CASGoogle Scholar
• 7 Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(2), 302–314 (1973).• First study describing cumulative dose as an important risk factor for anthracycline-induced cardiotoxicity (ACT).
  Medline CASGoogle Scholar
• 8 Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710–717 (1979).
  Medline CASGoogle Scholar
• 9 Kremer LC, Van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. 13(4), 503–512 (2002).
  Medline CASGoogle Scholar
• 10 Tukenova M, Guibout C, Oberlin O et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 28(8), 1308–1315 (2010).
  MedlineGoogle Scholar
• 11 Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24), 3754–3762 (2005).• First study investigating genetic polymorphisms associated with ACT.
  Medline CASGoogle Scholar
• 12 Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23(6), 1118–1126 (2009).
  Medline CASGoogle Scholar
• 13 Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112(12), 2789–2795 (2008).• First study investigating genetic polymorphisms associated with ACT in childhood cancer survivors.
  MedlineGoogle Scholar
• 14 Blanco JG, Sun CL, Landier W et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group. J. Clin. Oncol. 30(13), 1415–1421 (2012).•• Large study in childhood cancer survivors reporting on the role of a variant in CBR3 in ACT, particularly in patients receiving low-to-moderate cumulative doses of anthracyclines.
  Medline CASGoogle Scholar
• 15 Rajic V, Aplenc R, Debeljak M et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk. Lymphoma 50(10), 1693–1698 (2009).
  Medline CASGoogle Scholar
• 16 Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30(13), 1422–1428 (2012).•• Large pharmacogenetic study in childhood cancer survivors reporting multiple genetic risk variants for ACT and in particular identification and replication of an SLC28A3 variant.
  MedlineGoogle Scholar
• 17 Visscher H, Ross CJ, Rassekh SR et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer 60(8), 1375–1381 (2013).
  Medline CASGoogle Scholar
• 18 Carleton B, Poole R, Smith M et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol. Drug Saf. 18(8), 713–721 (2009).
  MedlineGoogle Scholar
• 19 Cancer Therapy Evaluation Program – Common Terminology Criteria for Adverse Events - Version 3. http://ctep.cancer.gov/reporting/ctc.html. Accessed 26 August 2011, (2003).
  Google Scholar
• 20 Altman AJ. Children's Oncology Group. Supportive care of children with cancer: current therapy and guidelines from the Children's Oncology Group. (3rd). Johns Hopkins University Press, Baltimore, MD, USA (2004).
  Google Scholar
• 21 Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74(1), 106–120 (2004).
  Medline CASGoogle Scholar
• 22 Visscher H, Ross CJ, Dube MP et al. Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics J. 9(6), 362–372 (2009).
  Medline CASGoogle Scholar
• 23 Brown AM, Renaud Y, Ross C et al. Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics 15(9), 1185–1195 (2014).
  CASGoogle Scholar
• 24 Bains OS, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J. Pharmacol. Exp. Ther. 335(3), 533–545 (2010).
  Medline CASGoogle Scholar
• 25 Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet. Epidemiol. 32(4), 361–369 (2008).
  MedlineGoogle Scholar
• 26 Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
  MedlineGoogle Scholar
• 27 Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 447(5), 666–676 (2004).
  Medline CASGoogle Scholar
• 28 Cano-Soldado P, Pastor-Anglada M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med. Res. Rev. 32(2), 428–457 (2012).
  Medline CASGoogle Scholar
• 29 Okabe M, Unno M, Harigae H et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 333(3), 754–762 (2005).
  Medline CASGoogle Scholar
• 30 Okabe M, Szakacs G, Reimers MA et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol. Cancer Ther. 7(9), 3081–3091 (2008).
  Medline CASGoogle Scholar
• 31 Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 12, 381 (2012).
  Medline CASGoogle Scholar
• 32 Bennett KM, Liu J, Hoelting C, Stoll J. Expression and analysis of two novel rat organic cation transporter homologs, SLC22A17 and SLC22A23. Mol. Cell Biochem. 352(1–2), 143–154 (2011).
  Medline CASGoogle Scholar
• 33 Cropp CD, Komori T, Shima JE et al. Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol. Pharmacol. 73(4), 1151–1158 (2008).
  Medline CASGoogle Scholar
• 34 Errasti-Murugarren E, Pastor-Anglada M. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics 11(6), 809–841 (2010).
  CASGoogle Scholar
• 35 Heintzman ND, Stuart RK, Hon G et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39(3), 311–318 (2007).
  Medline CASGoogle Scholar
• 36 Westra HJ, Peters MJ, Esko T et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45(10), 1238–1243 (2013).
  Medline CASGoogle Scholar
• 37 Ji Y, Moon I, Zlatkovic J et al. Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J. Pharmacol. Exp. Ther. 322(2), 529–540 (2007).
  Medline CASGoogle Scholar
• 38 Andrews PA, Brenner DE, Chou FT, Kubo H, Bachur NR. Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab. Dispos. 8(3), 152–156 (1980).
  Medline CASGoogle Scholar
• 39 Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271(7), 3460–3468 (1996).
  Medline CASGoogle Scholar
• 40 Zhang Y, El-Sikhry H, Chaudhary KR et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 297(1), H37–H46 (2009).
  Medline CASGoogle Scholar
• 41 Yee SB, Pritsos CA. Reductive activation of doxorubicin by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. Chem. Biol. Interact. 104(2–3), 87–101 (1997).
  Medline CASGoogle Scholar
• 42 Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem. 16(13), 1656–1672 (2009).
  Medline CASGoogle Scholar
• 43 Zhang S, Liu X, Bawa-Khalfe T et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18(11), 1639–1642 (2012).
  MedlineGoogle Scholar
• 44 L'ecuyer T, Allebban Z, Thomas R, Vander Heide R. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 286(6), H2057–H2064 (2004).
  MedlineGoogle Scholar
• 45 Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98(5), 1253–1260 (1996).
  Medline CASGoogle Scholar
• 46 Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 271(21), 12610–12616 (1996).
  Medline CASGoogle Scholar
• 47 Gao J, Xiong Y, Ho YS et al. Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim. Biophys. Acta 1783(10), 2020–2029 (2008).
  Medline CASGoogle Scholar
• 48 Bienengraeber M, Olson TM, Selivanov VA et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36(4), 382–387 (2004).
  Medline CASGoogle Scholar
• 49 Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 6, CD003917 (2011).
  Google Scholar
• 50 Lubieniecka JM, Liu J, Heffner D et al. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy. Cancer Epidemiol. Biomarkers Prev. 21(11), 2118–2120 (2012).
  Medline CASGoogle Scholar
• 51 Armenian SH, Ding Y, Mills G et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br. J. Haematol. 163(2), 205–213 (2013).• First study investigating the role of genetic polymorphisms in ACT after hematopoietic cell transplantation.
  Medline CASGoogle Scholar
• 52 Jungsuwadee P, Zhao T, Stolarczyk EI et al. The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Pharmacogenet. Genomics 22(4), 273–284 (2012).
  Medline CASGoogle Scholar
• 53 Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, Van Duijn CM. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet. Med. 8(7), 395–400 (2006).
  MedlineGoogle Scholar
• 54 Van Dalen EC, Van Der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst. Rev. 4, CD005008 (2009).
  Google Scholar
• 55 Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. 5, CD005006 (2010).
  Google Scholar